Peptide delivery

The fusion of an immunogenic peptide and the protein transthyretin protects the peptide antigen from proteolytic degradation, optimizes its uptake in local draining lymphatics and reduces its presentation in uninflamed distal lymphoid organs, as shown in mice.

An amphipathic peptide has been engineered and is capable of penetrating the blood–brain barrier as well as possessing a potent antiviral activity against Zika and other mosquito-borne viruses.

A study demonstrates that controlled integrin binding on a biomaterial was capable of promoting vascular cell sprouting and formation of a non-leaky blood vessel network in a healthy and diseased state.

Intracellular protein delivery has been a major challenge in the field of cell biology for decades. Engineering such delivery is a key step in the development of protein- and antibody-based therapeutics. Now, two different approaches that enable the delivery of antibodies and antibody fragments into the cytosol have been developed.

A subcutaneous depot of a diabetes drug fused to a thermosensitive biopolymer leads to blood-glucose control, for over one week after a single injection, in animal models of type-2 diabetes.